The SAFE score shows the greatest net clinical benefit in predicting 10-year cirrhosis risk among patients with noncirrhotic steatotic liver disease (SLD).
FIB-4 and APRI scores also demonstrate strong discrimination for cirrhosis, but SAFE outperforms others in net benefit analyses.
Risk scores for hepatocellular carcinoma (HCC) show limited clinical utility for surveillance decisions in noncirrhotic SLD.
Non-invasive fibrosis scoring and machine-learning models are emerging tools supplementing traditional risk scores, aiding early disease stratification.
